User login
To ensure breast health and reduce the risk of venous thromboembolic events, drug makers have developed oral contraceptives (OCs) with lower and lower doses of ethinyl estradiol. In the process, however, the beneficial effects of endogenous estradiol on bone acquisition have been suppressed. Therefore, the lowest-dose OC may not necessarily be the most appropriate clinical choice for adolescents and young women seeking contraception.
In this audiocast, Dr. Goldstein discusses:
- How low-dose OCs may affect a young woman’s bone mass accrual
- How to assure that young women reach the goal of peak bone mass while taking OCs
- Why more clinicians aren't aware of this issue
- The contraceptive methods he recommends for a young woman who is still building bone mass
- For which populations does he recommend low-dose OCs?
Dr. Goldstein is the author of Update on Osteoporosis (December 2013).
Steven R. Goldstein, MD, is Professor of Obstetrics and Gynecology at New York University School of Medicine in New York City. He is Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at New York University Medical Center in New York City. Dr. Goldstein serves on the OBG Management Board of Editors.
Steven R. Goldstein, MD, is Professor of Obstetrics and Gynecology at New York University School of Medicine in New York City. He is Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at New York University Medical Center in New York City. Dr. Goldstein serves on the OBG Management Board of Editors.
Steven R. Goldstein, MD, is Professor of Obstetrics and Gynecology at New York University School of Medicine in New York City. He is Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at New York University Medical Center in New York City. Dr. Goldstein serves on the OBG Management Board of Editors.
To ensure breast health and reduce the risk of venous thromboembolic events, drug makers have developed oral contraceptives (OCs) with lower and lower doses of ethinyl estradiol. In the process, however, the beneficial effects of endogenous estradiol on bone acquisition have been suppressed. Therefore, the lowest-dose OC may not necessarily be the most appropriate clinical choice for adolescents and young women seeking contraception.
In this audiocast, Dr. Goldstein discusses:
- How low-dose OCs may affect a young woman’s bone mass accrual
- How to assure that young women reach the goal of peak bone mass while taking OCs
- Why more clinicians aren't aware of this issue
- The contraceptive methods he recommends for a young woman who is still building bone mass
- For which populations does he recommend low-dose OCs?
Dr. Goldstein is the author of Update on Osteoporosis (December 2013).
To ensure breast health and reduce the risk of venous thromboembolic events, drug makers have developed oral contraceptives (OCs) with lower and lower doses of ethinyl estradiol. In the process, however, the beneficial effects of endogenous estradiol on bone acquisition have been suppressed. Therefore, the lowest-dose OC may not necessarily be the most appropriate clinical choice for adolescents and young women seeking contraception.
In this audiocast, Dr. Goldstein discusses:
- How low-dose OCs may affect a young woman’s bone mass accrual
- How to assure that young women reach the goal of peak bone mass while taking OCs
- Why more clinicians aren't aware of this issue
- The contraceptive methods he recommends for a young woman who is still building bone mass
- For which populations does he recommend low-dose OCs?
Dr. Goldstein is the author of Update on Osteoporosis (December 2013).
